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Abstract
Background: Angiogenesis plays an important role in tumor growth, invasion, and eventually
metastasis. Antiangiogenic strategies have been proven to be a promising approach for clinical
therapy for a variety of tumors. As a potent inhibitor of tumor angiogenesis, pigment epithelium-
derived factor (PEDF) has recently been studied and used as an anticancer agent in several tumor
models.
Methods:  A recombined adenovirus carrying PEDF gene (Ad-PEDF) was prepared, and its
expression by infected cells and in treated animals was confirmed with Western blotting and ELISA,
respectively. Its activity for inhibiting human umbilical vein endothelial cell (HUVEC) proliferation
was tested using the MTT assay. C57BL/6 mice bearing B16-F10 melanoma were treated with i.v.
administration of 5 × 108 IU/mouse Ad-PEDF, or 5 × 108 IU/mouse Ad-Null, or normal saline (NS),
every 3 days for a total of 4 times. Tumor volume and survival time were recorded. TUNEL, CD31
and H&E stainings of tumor tissue were conducted to examine apoptosis, microvessel density and
histological morphology changes. Antiangiogenesis was determined by the alginate-encapsulated
tumor cell assay.
Results: The recombinant PEDF adenovirus is able to transfer the PEDF gene to infected cells and
successfully produce secretory PEDF protein, which exhibits potent inhibitory effects on HUVEC
proliferation. Through inhibiting angiogenesis, reducing MVD and increasing apoptosis, Ad-PEDF
treatment reduced tumor volume and prolonged survival times of mouse bearing B16-F10
melanoma.
Conclusion: Our data indicate that Ad-PEDF may provide an effective approach to inhibit mouse
B16-F10 melanoma growth.
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Introduction
Melanoma is a malignant tumor derived from melano-
cytes which are found predominantly in skin but also in
the bowel and the eye. Approximately 160,000 new cases
of melanoma are diagnosed and around 48,000
melanoma-related deaths occur worldwide each year [1].
Despite many years of intensive research, surgical resec-
tion and systemic chemotherapy are still the main thera-
peutic strategies for malignant melanoma. Unfortunately,
for advanced melanoma, surgical resection is insuffi-
ciently effective while chemotherapy introduces signifi-
cant side effects [2]. Compared to other type of skin
cancer, melanoma is more rare but often associated with
a high mortality, accounting for 75% of all deaths from
skin cancer [3]. To explore new therapeutic agents/meth-
ods with less side effects is a major initiative in melanoma
research.
One hallmark of melanoma progression is angiogenesis,
which is induced by angiogenic factors released by tumor
cells and characterized as the formation of a new vascular
network from pre-existing blood vessels. Angiogenesis
facilitates tumor growth by supplying nutrients and oxy-
gen, while promoting tumor invasion and metastases [4].
Antiangiogenesis has been proposed as a therapeutic strat-
egy for cancer treatment since the 1970s, but it has been
limited by the unavailability of antiangiogenic agents
and/or inefficient administration methods. In the past
two decades, several antiangiogenic factors, such as angi-
ostatin, endostatin, thrombospondin and pigment epi-
thelium-derived factor (PEDF), have been found and
characterized [5]. As a new family of anti-tumor agent can-
didates, they are under active investigation by many
researchers. Accumulating data show antiangiogenic
agents have promising efficacy in tumor treatment [6].
Because PEDF selectively and potently suppresses new
vessel growth with least impact on pre-existing vessels, it
is one of the top candidates for tumor therapy [5].
PEDF is a 50 kDa glycoprotein that was first purified from
the conditioned medium of cultured primary human fetal
retinal pigment epithelial cells [7]. Later, it was found that
PEDF is widely expressed in human tissues, including the
adult brain, spinal cord, plasma, liver, bone, eye, heart,
and lung [5]. PEDF is a multi-functional serpin family
protein. It has been reported that it activates the Fas/FasL
death pathway and subsequently induces endothelial cell
death, and also regulates the balance between proang-
iogenic and antiangiogenic factors [8]. One prominent
feature of PEDF is the selective inhibition of neovascular-
ization, which is extremely important to minimize the
side effects in tumor treatment. The underlying mecha-
nism is still not well understood, but it has prompted sci-
entists to apply it in cancer treatment in a variety of forms
including purified, recombinant, PEDF peptide 327 to
343, and gene transfer [9]. Adenovirus is the widely uti-
lized gene transfer vehicle in a variety of gene therapies;
however, adenovirus-mediated gene transfer of PEDF for
tumor treatment is rarely reported.
In this study, we constructed a recombinant PEDF-
expressing adenovirus (Ad-PEDF) and tested its anti-
tumor efficacy in a mouse B16-F10 melanoma model.
Our data indicate that the Ad-PEDF treatment of
melanoma-bearing mice results in an increase of serum
PEDF and reduction of tumor angiogenesis, growth, and
animal death. The adenovirus-mediated gene transfer of
PEDF is thus a promising therapeutic strategy for
melanoma and other angiogenic tumors.
Methods
Recombinant adenovirus construction and viral 
preparation
According to the cDNA sequence of PEDF in genebank, we
designed a pair of PEDF primers that contain a Pme I
restriction site (underlined in the following) in both
primers (5'-AGCTTTGTTTAAACATGCAGGCCCTGGT-
GCTACTCCTC-3' and 5'-AGCTTTGTTTAAACTTAG-
GGGCCCCTGGGGTCCAGAATC-3'). Using these
primers, we amplified human PEDF cDNA with RT-PCR.
PCR product was digested with Pme I and its sequence
was confirmed. Using AdEasy system, we first clone PEDF
cDNA into a shuttle vector pAdenoVator-CMV5 at Pme I
and Bam H I site, in which PEDF expression is under the
control of the constitutive cytomegalovirus (CMV) pro-
moter. The recombinant shuttle plasmid was used to res-
cue the replication-defective adenovirus [10]. Ad-
luciferase and Ad-Null was prepared as the construction of
Ad-PEDF, except luciferase gene or no objective gene was
inserted.
The viral particles were amplified in human embryonic
kidney (HEK293) cells (ATCC Rockville Maryland, USA),
which were maintained in DMEM medium (Gibico BRL,
Grand Island, New York, USA) with 10% fetal bovine
serum (FBS) plus 100 μg/ml amikacin in a 37°C humidi-
fied chamber with 5% CO2 atmosphere. The harvested
viral particles from the cultures were purified by double
cesium chloride (CsCl) gradient ultracentrifugation fol-
lowed by dialysis. Final aliquots of virus were measured
by absorption (A260). The virus titer was quantified using
a standard TCID50 assay.
Cell culture and adenovirus infection
Primary human umbilical vein endothelial cells
(HUVECs) were collected and cultured as previously
described [11]. The CT26 mouse colon carcinoma and
B16-F10 mouse melanoma cell lines were purchased from
the American Type Culture Collection (ATCC, Rockville
Maryland, USA) and cultured in RM1640 mediumJournal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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(Gibico BRL, Grand Island, New York, USA) supple-
mented with 10% FBS and 100 μg/ml amikacin. 2.5 × 105
CT26 or B16-F10 cells were plated into 6-well plates and
grew to 70%~80% confluence. The cells were washed
three times gently by serum-free medium and infected
with Ad-PEDF or Ad-null (both at MOI50, 2.5 × 107 pfu
per 5 × 105 cells) in 0.5 ml serum-free medium, with nor-
mal saline as the non-infection control. After incubation
for 90 minutes at 37°C, 1.5 mL complete medium with
10% FBS was added to wells. Supernatants were collected
after further culture for 72 hours and stored at -80°C for
further analysis.
Western blotting analysis
Western blot analysis was performed as described previ-
ously [12]. Briefly, the supernatant was concentrated by
super filter (5 kDa, Minipore) and mixed with an equal
volume of sodium dodecyl sulfate (SDS) sample buffer.
The proteins were separated by SDS-polyacrylamide gel
electrophoresis (PAGE) and electronically transferred
onto a polyvinylidene difluoride membrane (PVDF, Bio-
Rad, Richmond, CA, USA). The blots were probed with a
mouse anti-human PEDF monoclonal antibody (3:1000,
mAb; R&D Systems, Boston, Massachusetts, USA) plus a
peroxidase-conjugated secondary antibody, goat anti-
mouse IgG (1:10,000, ZSGB-BIO, Beijing, China). The
protein bands were visualized using an enhanced chemi-
luminescence (ECL) detection system (Pierce, Rockford,
Illinois, USA).
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium 
bromide (MTT) colorimetric assay
The MTT Assay was used to determine the effect of PEDF
derived from Ad-PEDF infected cells on human umbilical
vein endothelial cells (HUVECs). Three types of superna-
tants from B16-F10 cells infected with Ad-PEDF, Ad-Null
or NS, respectively, were prepared as described above.
Each type of supernatant was further diluted into a series
of 1/2 dilutions in six tubes (from 1:2 to 1:64). Each
supernatant dilution was added into triplicate wells (50
μl/well) of HUVECs which were seeded on 96-well plates
on the previous day (2 × 103 cells in 50 μl complete
medium per well). The cells were incubated at 37°C in 5%
CO2 for 72 hours. Then, each well received 10 μl MTT
solution (5 mg/mL). After a 4-hour incubation, the media
was removed and 150 μl dimethyl sulfoxide was added.
After 20 min of incubation, the OD value was determined
by a microplate reader (3550-UV, BIO-RAD, USA)[13].
The following formula was used to calculate the inhibi-
tion rate of HUVEC proliferation: [1 - (experimental
group OD value - negative control OD value)/(positive
control OD value - negative control OD value)] × 100%.
Animal experiments
Six to 8 week-old female C57BL/6 and BALB/c mice were
purchased from the West China Experimental Animal
Center of Sichuan University (Sichuan, China). Mice were
permitted 1 week to acclimate to their environment
before manipulation. All surgical procedures were com-
pleted in accordance with the guidelines on the care and
use of laboratory animals for research purposes by the
West China Hospital Cancer Center's Animal Care and
Use Committee. C57BL/6 mice were inoculated with 1 ×
105 B16-F10 melanoma cells s.c. in the right flank. Pri-
mary tumors usually became palpable on day 7–8 and
with an average diameter of 3 mm. On day 9, the tumor-
bearing mice were randomly assigned into 3 groups and
each group contained 8 mice. Each mouse in Ad-PEDF
group received 5 × 108 IU Ad-PEDF virus in 0.1 ml via i.v.
injection on day 9, 12, 15, and 18 with a total of 4 times.
The mice in the control groups received 5 × 108 IU Ad-
Null or normal saline (NS), serving as vector and injection
control, respectively. The details of the treatment were
described previously [14]. Tumor dimensions were meas-
ured with calipers on day 9, 12, 15, 18, 21 and 24 with a
total of 6 times. The tumor volumes were calculated
according to the following formula: length × width2 ×
0.52. Two mice from each group were bled to collect
serum on day 22, which was used to examine the PEDF
concentration in serum. Surviving mice in Ad-PEDF
groups were monitored up to 42 days; all other mice
become moribund by day 24 and were sacrificed. Subcu-
taneous tumors from sacrificed mice were removed and
fixed in 4% formaldehyde solution for immunochemistry
staining and histological analysis.
Detection of PEDF concentration in serum
Concentrations of PEDF in serum were determined using
a commercial PEDF ELISA kit (ADL, Biotech. Dev. Co.,
USA) following the manufacturer's instructions. Briefly,
50 μl serum and 50 μl PEDF monoclonal antibody were
added to every well of the pre-coated ELISA plate and the
plate was incubated at 37°C for 1 hour. After wash, 80 μl
of streptavidin-HRP was added and incubated at 37°C for
30 minutes. After wash, 50 μl substrate A and B was
added, respectively, and incubated for 10 minutes at
37°C, followed by 50 μl stop solution. The absorbance
was read immediately at 450 nm in a spectrophotometer
[15]. There were 2 serum samples in each group, and each
sample were applied to 3 replicated wells.
Luciferase assay for virus distribution
Virus distribution was analyzed using the luciferase
reporting system, as reported previously [16]. C57BL/6
mice were inoculated with 1 × 105 B16-F10 melanoma
cells s.c. in the right flank. On day 9, the tumor-bearing
mice were randomly assigned into 2 groups and each
group contained 3 mice. Experimental group received 5 ×Journal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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1010 IU Ad-luciferase and control group received 5 × 1010
IU Ad-null virus in 0.1 ml via i.v. injection. Seven days
later, the mice were sacrificed. Heart, liver, spleen, lung,
kidney and tumor from each mouse were collected and
individually stored in liquid nitrogen. Using a luciferase
assay system kit (Promega, Madison WI, USA), we ana-
lyzed luciferase expression in each type of collected organ,
according to the manufacturer's instructions. Briefly, the
same organs from the same group were pooled and
ground to a fine powder in a mortar containing liquid
nitrogen. The fine powder was dissolved and further proc-
essed in CCLB solution in the assay kit. The resultant
supernatants were collected and subjected to determina-
tion of relative light units (RLU, synergy 2, Biotek, Ger-
many), along with a group of standard samples in the kit.
The amount of luciferase in each sample was calculated
on the basis of the standard curve.
Detection of apoptosis and microvessel density (MVD)
On day 24 after mouse inoculation with melanoma cells,
subcutaneous tumors from Ad-PEDF, Ad-null and NS
treated mice were collected, fixed, embedded in paraffin,
and cut into 3–5 μm sections. The apoptotic cells within
the tumor tissue were evaluated using the DeadEnd Color-
imetric Terminal Deoxynucleotidyl Transferase-Mediated
dUTP Nick-End Labeling (TUNEL) System (Promega,
Corporation, Madison, Wisconsin, USA) following the
manufacturer's protocol. Ten high power fields on each
slide and three slides from each animal were examined.
Apoptosis index was calculated by dividing the number of
apoptotic cells by the total number of cells in the field.
The method reported by Weidner et al was adopted to
quantify MVD in tumor tissues [17]. Briefly, 5 μm tumor
sections were stained for the epithelial cell marker, CD31.
The procedure of immunostaining for CD31 was previ-
ously described in detail [18]. The following antibodies
and reagents were used: goat anti-mouse CD31 mAb
(1:200, Santa Cruz Biotechnology, Santa Cruz, California,
USA), biotinylated polyclonal rabbit anti-goat (1:100,
Santa Cruz Biotechnology, Santa Cruz, California, USA),
ABC kit (Boster biological engineering company, Wuhan,
China) and DAB visualization system (ZSJQ Biotechnol-
ogy, Beijing, China). The resultant sections were first
examined at low magnifications (×40 and ×100) to iden-
tify the vascular-rich area in the tumor. Within this area,
the CD31-positive microvessels were counted in a single
high-power (×200) field. Any CD31 stained single or clus-
ter of cells was considered a single countable microvessel.
Adjacent sections were stained with hematoxylin and
eosin (H&E) and examined for tissue structure and histo-
logical morphology. Each group contains 2 mice, and 3
sections from each mouse.
Alginate-encapsulated tumor cell assay
The alginate-encapsulated tumor cell assay was used to
measure tumor angiogenesis in vivo, as previously
described [14,18]. Briefly, B16-F10 or CT26 cells in 1.5%
(m/v) sodium alginate solution (Sigma-Aldrich, St. Louis,
Missouri, USA) was dropped into a swirling 0.25 M CaCl2
solution to prepare alginate beads (1 × 105 cells/bead).
Four resultant beads were implanted s.c. on both dorsal
sides of BALB/c female mice (2 beads/side). On the next
day, mice were randomly assigned into 3 groups (n = 2),
and each group was i.v. injected with 0.1 ml Ad-PEDF (5
× 108IU/mouse), Ad-Null (5 × 108 IU/mouse), or NS,
respectively. After a week, this same treatment on each
mouse was repeated. On day 11 after tumor cell implan-
tation, all mice were injected i.v. with 100 μl FITC-dextran
(Sigma-Aldrich, St. Louis, Missouri, US) solution (100
mg/ml), which is a plasma-borne tracer extravasating into
tissue interstitial fluid from plasma within 20 minutes.
Alginate beads were exposed surgically and photographed
with a digital camera (model, Canon, Japan). Then, the
beads were removed and vortexed in a tube containing 2
ml NS. After centrifugation, the supernatant was collected
and subjected to a fluorescence spectrophotometer for the
measurement of fluorescence intensity. The amount of
FITC-dextran was calculated and used to estimate the
amount of blood supply and angiogenesis status.
Statistical analysis
SPSS program (version 15.0, SPSS Inc., USA) was used for
statistical analysis. Log-rank test was used to compare sur-
vival rate among groups. ANOVA was used to determine
statistical significances in remaining comparisons in this
study. The difference is considered as significant if p <
0.05.
Results
Recombinant Ad-PEDF virus successfully transferred PEDF 
gene into tumor cells and produced secretory PEDF 
protein in vitro
Whether an adenovirus-mediated gene transfer is success-
ful or not mainly depends on its capacity to infect host
cells and express the recombinant gene. Therefore, we first
tested whether our recombinant Ad-PEDF virus is capable
of infecting cells and expresses PEDF protein in vitro. CT26
and B16-F10 cell lines were infected with Ad-PEDF, Ad-
null or treated with normal saline (NS). Three types of
supernatant from each cell line were prepared and sub-
jected to Western blotting analysis. As shown in Fig. 1,
PEDF was detected in supernatant from both cell lines
infected by Ad-PEDF virus, but neither in Ad-null infected
nor NS treated cells. These results indicate that our recom-
binant adenovirus successfully transfers the PEDF gene
into cultured cells and produces secretory protein.Journal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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PEDF protein from Ad-PEDF infected cells exhibited a 
potent inhibitory effect on HUVEC proliferation
Next, we tested whether Ad-PEDF from infected cell pos-
sess inhibitory bioactivity on the proliferation of epithe-
lial cells. Using the MTT assay, we measured HUVEC cell
proliferation and viability after treatment of supernatant
from Ad-PEDF infected B16-F10 cells or control superna-
tant. As shown in Fig 2, supernatant from Ad-PEDF
infected B16-F10 cells significantly inhibited the prolifer-
ation of HUVEC with an inhibitory rate of 68.8% ± 1.5%
at a 1:2 dilution. Furthermore, this inhibitory rate declines
with the increase of dilution, suggesting a dose-dependent
effect. In contrast, the control supernatant from Ad-Null
infected or NS treated B16-F10 cells had no effect on
HUVEC proliferation, which did not change with the dilu-
tion. These results indicate that secretory PEDF is func-
tional and capable of mediating a potent inhibitory effect
on HUVEC proliferation.
Ad-PEDF treatment inhibited tumor growth in vivo and 
prolonged the survival time of the tumor-bearing mice
After confirmation of the success for PEDF gene transfer
and expression of functional PEDF protein in vitro, we
examined the anti-tumor efficacy of Ad-PEDF treatment
in a mouse tumor model. As shown in Fig 3A, from day 21
after tumor cell inoculation, the tumor volume in Ad-
PEDF treated mice started to show significant differences
from those in controls (p < 0.05). Tumor volumes in the
Ad-PEDF treated group was 1447.8 ± 244.4 mm3, in con-
trast to 2337.4 ± 365.8 mm3 in Ad-Null group and 2578.2
± 406.7 mm3 in NS group on day 21. On day 24, the
tumor size in Ad-PEDF, Ad-null and NS groups were
2195.1 ± 462.9 mm3, 4013.3 ± 518.3 mm3, and 4361.3 ±
569.6 mm3, respectively. The time of mouse death was
recorded and used to calculate the survival rate. As shown
in Fig 3B, the NS treated group showed 50% survival at
day 13 and 0% on day 23, and the Ad-null group showed
50% survival at day 14 and 0% on day 24. In contrast, Ad-
PEDF group had a 50% survival rate at day 38 and per-
sisted up to day 42. Log-rank test indicated that survival
rate in Ad-PEDF group is significantly higher than in con-
trol groups (p < 0.05)
Ad-PEDF treatment increased serum PEDF and adenovirus 
mainly distributed in liver
To assess whether the above observed smaller tumor vol-
ume and increased survival rate in Ad-PEDF group is asso-
ciated with the effect of PEDF, we measured PEDF
concentration in the serum. As shown in Fig 4A, on day 22
after tumor cell inoculation, PEDF level in Ad-PEDF group
was significantly higher than control groups, 77.36 ± 3.78
ng/ml vs 33.62 ± 2.79 ng/ml in Ad-null and 36.87 ± 3.35
ng/ml in NS groups, respectively (p < 0.05). This result
indicates that Ad-PEDF successfully transferred PEDF to
mice and produced secretory PEDF proteins.
Next, we determined the source of PEDF by analyzing the
distribution of i.v. injected virus. As shown in Fig 4B,
using the luciferase reporting system, we found that the
viruses mainly distributed in the liver, in agreement with
many adenovirus infection models. This result suggests
that while Ad-PEDF infected multiple organs, including
the tumor, the liver is the major organ that adenovirus tar-
Expression of human PEDF in Ad-PEDF infected cell lines Figure 1
Expression of human PEDF in Ad-PEDF infected cell 
lines. Supernatant from Ad-PEDF, Ad-Null infected and nor-
mal saline (NS) treated CT26 and B16-F10 cells were col-
lected and subjected to Western blot analysis with an anti-
human PEDF mAb. Human PEDF was detected as a single 
band of 50 KDa in Ad-PEDF infected cells, but neither in Ad-
null infected nor NS-treated cells.
Inhibitory effect of recombinant PEDF on HUVEC prolifera- tion in vitro Figure 2
Inhibitory effect of recombinant PEDF on HUVEC 
proliferation in vitro. The culture supernatants were col-
lected from Ad-PEDF, Ad-null infected and NS treated B16-
F10 cells. A 1:2 dilution series of each supernatant were fur-
ther prepared and applied to HUVEC cells. The proliferation 
of HUVEC was measured with an MTT assay. The superna-
tant from Ad-PEDF infected cells inhibited the proliferation 
of HUVEC in a dose-dependent manner.Journal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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geted and likely is the significant source of the serum
PEDF.
Ad-PEDF treatment increased apoptosis and decreased 
MVD in tumor tissue
In the proceeding experiments, we observed the reduced
tumor volume and increased serum PEDF after Ad-PEDF
treatment, in comparison to control, however, the major-
ity of the virus was entrapped in liver and did not target
the tumor tissue. It is important to demonstrate whether
serum PEDF indeed acts on tumor tissue and causes histo-
logical change. To address this question, we determined
apoptosis in tumor tissue after Ad-PEDF treatment using
TUNEL staining. As shown in Fig 5A, within a similar field
of view, may more apoptotic cells (with green nuclei) in
tumor tissues were observed in Ad-PEDF treated mice
than in Ad-null or NS treated mice. For the quantitative
comparison, the apoptosis index in each group was calcu-
lated. The apoptosis index was significantly higher in Ad-
PEDF group than in Ad-Null and NS groups with values of
26.3% ± 3.3% v.s. 6.3% ± 4.7% and 5.6% ± 1.9%, respec-
tively (p < 0.05, Fig 5B). These data suggest that decreased
tumor volumes after Ad-PEDF may be caused by increased
apoptosis.
To further determine whether the increase in apoptosis of
Ad-PEDF treated tumor tissue was associated with the
antiangiogenic effect of PEDF, we analyzed MVD of tumor
tissues in each group. As shown in Fig 5C, intensive CD31
Anti-tumor efficacy of Ad-PEDF in vivo Figure 3
Anti-tumor efficacy of Ad-PEDF in vivo. Three groups 
of C57BL/6 mice bearing B16-F10 melanoma were treated 
with NS or 5 × 108 IU Ad-PEDF or Ad-Null at day 9, 12, 15, 
18 and 21 after inoculation, respectively. Tumor sizes on 
each mouse were measured every 3 days and survival in each 
group was monitored daily. A. Significant differences were 
found in tumor volume (p < 0.05) between Ad-PEDF treated 
and the control groups. B. Significant increase of survival rate 
and prolonged survival times were observed in Ad-PEDF 
treated mice (log-rank test, *, p < 0.05, vs controls). n = 8.
Serum PEDF and viral distribution in mice after Ad-PEDF  treatment Figure 4
Serum PEDF and viral distribution in mice after Ad-
PEDF treatment. A. Serum collected from mice bearing 
B16-F10 melanoma on day 22 after tumor inoculation was 
processed and subjected to an ELISA analysis to measure 
PEDF concentration. Compared to Ad-null or NS treated 
mice, serum PEDF concentration significantly increased in 
mice treated with Ad-PEDF (ANOVA, *, p < 0.05). B. The 
distribution of i.v. injected virus. The luciferase content rep-
resents the amount of virus. n = 2.Journal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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immunoreactive microvessels was observed in tumor tis-
sue from mice treated by NS and Ad-null, but only mod-
erate CD31 staining present in tumor tissue from mice
treated by Ad-PEDF. For comparison, CD31-positive sin-
gle or a cluster of cells were counted as the microvessels,
and MVD was calculated for each group with the formula
described in the materials and methods. MVD of tumor
tissues from Ad-PEDF treated mice exhibited a significant
decrease than from Ad-null or NS treated mice, (21 ± 4,
54.3 ± 7.2, 62 ± 6.5, respectively) (p < 0.05, Fig 5D). These
data suggest that the decreased angiogenesis after Ad-
PEDF treatment may be responsible for the increased
apoptosis.
Adjacent sections were stained with H&E to evaluate the
morphologic changes after Ad-PEDF or control treat-
ments. Consistent with the results of CD31 immuno-
chemistry staining, less vessels and remarkable necrosis
areas were observed in tumor tissue from Ad-PEDF treated
mice in comparison to Ad-null or NS treated mice (Fig
5E). Collectively, these data suggest that serum PEDF from
infected host cells is sufficient to inhibit tumor angiogen-
esis, subsequently promote apoptosis, reduce tumor pro-
gression and prolong survival time.
Ad-PEDF treatment inhibited the development of tumor 
angiogenesis
To confirm the proceeding finding that PEDF from Ad-
PEDF gene transfer is associated with the reduction of
tumor angiogenesis, and to directly demonstrate the
causal relationship, we performed the alginate-encapsu-
lated tumor cell assay, which is capable of demonstrating
whether the development of tumor angiogenesis is pre-
vented by PEDF treatment. As shown in Fig 6, the intensity
of blood vessels on the surface of tumor cell-containing
alginate beads was noticeably less in Ad-PEDF-treated
mice than Ad-null or NS treated mice (Fig 6A). The quan-
tification results for the amount of FITC-dextran indicate
that the distribution of extravasated tracer in the encapsu-
lated tumor tissues was consistent with the distribution of
blood vessels on the bead surface; the amount of FITC-
dextran per beads in Ad-PEDF, Ad-null and NS group was
2.1 ± 0.3 μg/bead, 5.8 ± 0.3 μg/bead and 6.2 ± 0.6 μg/
bead, respectively. Similarly, an experiment with encapsu-
lated B16-F10 cells has been performed and its result was
similar to the result for CT-26 cells. (Data were not
shown). These data confirmed that Ad-PEDF-mediated
PEDF gene transfer and expression is responsible for the
inhibition of tumor angiogenesis in the studied tumor
model.
Discussion
Angiogenesis is required for a variety of physiological and
pathological processes. It is a complex biological process
under precise regulation of multiple factors in multiple
steps [19]. There are two groups of reciprocally antagoniz-
ing factors, proangiogenitors and antiangiogenitors. The
TUNEL, CD31 and histological staining for tumor tissue Figure 5 (see previous page)
TUNEL, CD31 and histological staining for tumor tissue. On day 24 following inoculation, tumor tissue from tumor-
bearing mice treated with NS (a), Ad-Null (b), or Ad-PEDF (c) were sectioned and stained with FITC-dUTP, CD31 mAb or 
H&E. A. Apoptotic cells (green) were identified by TUNEL and examined under a fluorescence microscope (Original magnifica-
tion, ×200). B. ANOVA analysis detected significant differences in the apoptotic index between Ad-PEDF group and control 
groups (p < 0.05). C. Micrographs show tumor tissue sections stained with anti-CD31 antibody (Original magnification, × 200) 
after NS, Ad-Null or Ad-PEDF treatment. D. Quantitative results for microvessel density (MVD) in tumor tissue. Ad-PEDF 
group shows a significant decrease of MVD compared to control groups (p < 0.05). E. Micrographs show tumor tissue sections 
stained with H&E. Decreased density of vessels and noticeable necrosis was observed in tumors from Ad-PEDF treated mice 
(c). In contrast, tumor cells grew well with less necrosis in NS (a) or Ad-Null group (b). (Original magnification, ×400). n = 2; 3 
sections/mouse.
Alginate-encapsulated tumor cell assay for the inhibition of  angiogenesis Figure 6
Alginate-encapsulated tumor cell assay for the inhibi-
tion of angiogenesis. Mice bearing alginate beads contain-
ing CT26 tumor cells were treated with NS, Ad-Null, or Ad-
PEDF twice on day 1 and 8, respectively. On day 11, all mice 
received an injection of FITC-dextran and were sacrificed 20 
min later. A. Photographs show surface of alginate beads 
from different groups. B. FITC-dextran uptake in the tumor 
tissue was significantly decreased in mice treated with Ad-
PEDF compared to mice treated with NS (a) or Ad-Null (b) 
group (p < 0.05). n = 2; 4 beads/mouse.Journal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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former includes vascular endothelial growth factor
(VEGF), platelet-derived growth factor (PDGF), basic
fibroblast growth factor (b-FGF) and fibroblast growth
factor (FGF), and the latter includes angiostatin, endosta-
tin, thrombospondin and PEDF. PEDF is notable for its
inhibitory function responsible for the avascularity of
ocular compartments by opposing the angiogenic effect of
VEGF in eye. It has been shown that PEDF is the most
potent endogenous inhibitor of angiogenesis; its potency
is twice that of angiostatin and seven times of endostatin
[5,20]. Recently, data showed that PEDF also plays impor-
tant roles in regulating normal development and tumor
growth. For example, a recent study showed that the
expression of PEDF is inversely proportional to the expres-
sion of VEGF at the growth plate of cartilage and is
involved in the control of osteosarcoma [21]. In addition,
it has been reported that PEDF could significantly inhibit
neuroblastoma and Wilms' tumor [22,23]. A decrease of
PEDF results in a tumor-permissive environment and pro-
motes tumor growth and metastasis [9]. It is generally
thought that PEDF's anti-tumor activity is the extended
function of its antiangiogenic effect, decreasing microvas-
cularity and blood supplying.
In the past decade, researchers have prepared various
forms of PEDF and demonstrated its beneficial effects in
several tumor models. Doll et al reported that exogenous
recombinant PEDF protein induced tumor epithelial
apoptosis in mouse prostate and pancreas [24]. Liu et al
showed that a short peptide derived from the parent PEDF
molecule was able to inhibit osteosarcoma growth [25].
Streck et al reported that adeno-associated virus (AAV)
delivering PEDF gene treatment successfully restricted
human neuroblastoma engraftment in a dose-dependent
fashion [22]. Hase et al demonstrated that intratumoral
injection of a lentivirus vector encoding PEDF resulted in
inhibition of human pancreatic cancer in nude mice [20].
Moreover, Wang et al showed that in vivo transfer of PEDF
mediated by adenoviral vectors exerted a dramatic inhibi-
tion of tumor growth in athymic nude mice implanted
with the human HCC and in C57BL/6 mice implanted
with mouse lung carcinoma [26]. In the present study, we
investigated the adenovirus-mediated PEDF gene transfer
and tested its anti-tumor effect in a mouse model of
melanoma.
Melanoma, a tumor derived from neuroectoderm, has a
high malignancy with poor prognosis, due to the vascular
and lymphatic metastasis during the late stage [27]. The
outcomes of existing therapeutic protocols are very poor.
Thus, the development of novel treatment approaches is
required [28]. Since the neovascularization is one critical
underlying mechanism of vascular and lymphatic metas-
tasis, the current study was designed to investigate
whether overexpression of PEDF mediated by adenovirus
gene transfer is a potential approach to suppress tumor
angiogenesis and inhibit melanoma growth. Encourag-
ingly, we constructed a recombinant PEDF adenovirus
that is capable of transferring PEDF gene producing secre-
tory PEDF protein both in vitro and in vivo. Furthermore,
we showed that the secretory PEDF is a functional protein
with potent inhibitory effects on HUVEC proliferation.
More importantly, tumor-bearing mice exhibited signifi-
cantly reduced tumor volume and prolonged survival
time after Ad-PEDF treatment. Finally, we demonstrated
that Ad-PEDF exerted anti-tumor activity through inhibit-
ing angiogenesis, reducing MVD and increasing apopto-
sis.
Adenovirus type 5 is an established and widely used vec-
tor for the delivery of therapeutic genes [29]. Although
there is no evidence to prove Ad-PEDF has a stronger ther-
apeutic effect on tumors than other PEDF patterns, the
adenovirus vector has several properties that make it par-
ticularly promising for gene therapy. First, the adenovirus
vector can efficiently transfer genes to both dividing and
quiescent cells both in vivo and in vitro, and importantly
possesses high stability in vivo. Additionally, adenovirus
vector can be produced at high titer conveniently, which
is essential for clinical utility. Finally, as opposed to the
retrovirus vector such as lentivirus, adenoviral DNA does
not usually integrate into host cell's genome and therefore
has a very low risk of generating tumorigenic mutations.
Adenovirus-related pathology is mostly limited to mild
upper respiratory tract infections [30,31].
It is very encouraging that Ad-PEDF treatment resulted in
a high level of PEDF expression in serum and caused the
inhibition of tumor growth. However, a few questions
were left unaddressed in this study. First, this study mainly
focused on the primary tumor, it is unknown whether Ad-
PEDF treatment is effective in controlling late stage tumor
growth, metastasis, and tumor growth in a metastasis site.
Based on the assumption that Ad-PEDF may be mainly
used as an option for advanced melanoma treatment,
investigation of the effect of Ad-PEDF treatment for a late
stage melanoma is critical to evaluate its potential clinical
value, which is one of our future directions. In addition,
adenovirus is highly immunogenic, which induces major
humoral and cellular immune response when adminis-
tered systemically [30]. These immune responses result in
a quick clearance of virus when they are re-administered.
While the adenovirus-induced humoral immune
response leads to the antibody-mediated neutralization of
virus in circulation, the cell-mediated immune response
results in lysis of adenovirus-infected cells and loss of
transferred gene. To prevent this quick clearance, we
treated animals with multiple injections of Ad-PEDF every
3 days in this study. Although we used a lower dose than
in the literature, the optimal window for effective doseJournal of Experimental & Clinical Cancer Research 2009, 28:75 http://www.jeccr.com/content/28/1/75
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and toxicity of this treatment is still to be determined. Fur-
thermore, consistent with previous observation, Ad5,
used in the present study was mainly directed to the liver,
probably, via the vitamin K-dependent coagulation
zymogens or other plasma protein-directed mechanisms
[32]. We speculate that the secretory PEDF from non-
tumor tissues is first released into the blood, then circu-
lates to tumor tissue and exerts the antiangiogenesis effect.
It appears not necessary to avoid the liver uptake of virus
in our model and liver is probably the major source of the
serum PEDF after Ad-PEDF treatment. However, because
of the potential and undefined side effects and to further
increase anti-tumor efficacy, modification of vector or
optimization of delivery route to direct viruses into tumor
tissue is critical to translate this study to an applicable
therapeutic option for patients.
It has been shown that the liposome system can reduce
adenoviral immunogenicity, increase localization of
virus, and allow successful re-administration of the virus
without loss of gene expression efficiency [16]. Therefore,
we developed an Ad-PEDF-liposome system and are
under active investigation, aiming to address the above
mentioned unanswered issues. In addition, to further
increase efficacy and limit side effects, we are also explor-
ing the bi-specific antibody strategy to retarget the Ad-
PEDF adenovirus to melanoma tumor tissue, as Reynolds
et al prepared a targetable adenovirus-mediated gene
transfer to pulmonary endothelium [33,34]
In summary, until the current study, research for experi-
mental melanoma treated with Ad-PEDF had not been
reported. Our data validate that Ad-PEDF treatment can
exert an inhibitory effect on tumor angiogenesis. While
the adenovirus-mediated PEDF gene therapy may provide
a promising approach for primary melanoma treatment,
we are still exploring the strategies for reducing its side
effects and improving the tropism of Ad-PEDF to tumor.
Conclusion
Our study indicates that adenovirus-mediated PEDF gene
transfer and expression can provide an effective approach
to inhibit primary mouse B16-F10 melanoma growth.
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